slot game 49 jili
Bengals quarterback Joe Burrow’s home was broken into Monday night while he played against the Cowboys, the latest in a series of thefts committed during games. Chiefs stars Patrick Mahomes and Travis Kelce had their homes broken into the day before a game and then the day of a game in October. Bears players said they plan on being cautious when the team plays on “Monday Night Football.” “It was happening before, but now it’s happening to big names and it’s a big matter,” receiver DJ Moore said Friday. “So, I’m taking it serious. ...You definitely have to worry about it.” Tight end Cole Kmet, the team’s NFLPA representative, said that the Bears security staff offers services to their players, be it actual guards or technology, when they’re on the road. The union also offers discounts for home security systems, he said. “Things are very accessible nowadays in terms of being able to look things up, where people live ...” Kmet said. “[It’s] definitely something that as a player you’ve gotta be aware of, because I would say at this point everyone kinda knows your schedule. They know when the house is occupied and when it’s not. It’s unfortunate, but it’s part of the deal.” Moore warned that he has a premium security system. “My house is wired like the Bat-cave,” he said. “You ain’t getting in. If you touch the house, the alarm goes off.” Hoke on Tyrique One day after cornerback Tyrique Stevenson said he didn’t want his Fail Mary gaffe to define him, cornerbacks coach Jon Hoke said he had a lot to deal with in the aftermath of the Commanders’ game-winning touchdown. “Let’s be honest: It’s a tough one, especially in this city where football matters,” Hoke said. “He gets introduced the next game and he gets booed and all that. It’s tough.” Hoke acknowledged the effect of the gaffe— “We had some tough games after that,” he said — but said sensed that Stevenson’s teammates remained supportive. “Players are truly forgiving of teammates, they really are,” he said. “That’s what make it unique about sport, is they do protect each other.” Swift still out Running back D’Andre Swift missed his second consecutive practice because of a groin injury but offensive coordinator Chris Beatty expects him to practice Saturday. “It’s one of those things where we are just trying to be prudent with it and also be able to be prepared for however the game presents itself,” he said. “I think he will be able to do what he does, but we are also prepared whatever way that may go.” Other Bears players who missed practice were guard Ryan Bates (concussion), defensive tackle Gervon Dexter (knee), running back Roschon Johnson (concussion) and tight end Marcedes Lewis (veteran rest). Cornerback Josh Blackwell (shoulder) was upgraded to limited. Safety Elijah Hicks (ankle) was limited, too. Notes • Special teams coordinator Richard Hightower called former Bears kicker Robbie Gould, who was named the head coach at St. Viator this week, “as detailed as a person I have ever been around.” Kmet, who went to St. Viator, said he was excited by the development. “It’ll be cool to see,” he said. “I’ll be rooting Robbie on heavily here.” • Kmet declared U.S. Bank Stadium his favorite, saying it “feels like you’re in a ‘Game of Thrones’ set.” Reminded that Bears president/CEO Kevin Warren helped build it, Kmet said he’d like one of his own. “That one’s pretty beautiful,” he said. “So yeah, hopefully something like that.” • The Vikings had one player not practice Friday: cornerback Stephon Gilmore, who has a hamstring problem.
China Sanctions US Companies, Executives Over Arms Sale to Taiwan
(TNS) — Supremacy in the race to self-drive an electrified auto industry is harder than the masters of Detroit and Silicon Valley figured, proving that what players do is far more important than what they say. General Motors Co. showed as much this week with after pumping $10 billion into it and seeing nothing but more of the same for years to come. Talk about sunk cost: the capitulation effectively cedes an allegedly multibillion-dollar opportunity to Google parent Alphabet’s Waymo AV unit, Elon Musk’s Tesla Inc. and what one industry analyst calls China EV Inc. That must rankle atop GM because it’s not how the reinvention of the mother of all legacy automakers was supposed to evolve in this allegedly post-industrial age. Under CEO Mary Barra, GM’s been pushing to reinvent its workforce, restore its product cred and recast its core identity into a next-gen digital automaker deserving a higher share price delivering more value to investors. Mission accomplished — sort of. GM’s robotaxi retreat and redeployment of precious capital feels faintly like a replay of an old, familiar melody in the Detroit automaker's history: in the mid-1990s, reminds Tu Le in his latest Sino Auto Insights newsletter, GM launched a connected vehicle service it still operates called OnStar and fielded for just a few years an EV for the masses dubbed EV1. "The ideas and the ambitions were spot on," he writes, "but either the bean counters and/or management didn't have the stomachs to see these technologies through. Cruise is likely gonna be another one of those missed opportunities for GM." Cruise's exit from its robotaxi program also is a reminder that all sides of this competitive equation — big tech, startups, legacy autos, the investor class — are finding the technological journey, the financial demands and the regulatory scrutiny far more difficult and far more expensive than they figured when they bet on the inevitability of an electrified auto industry driving itself by ... well, soon. “The announcement is also a black eye for the credibility of GM management that, as recently as last year, told investors the Cruise business could generate $50 billion in annual revenue by 2030,” wrote Garrett Nelson, senior equity analyst at CFRA Research. “We think investors were losing patience with its hefty spending (on) robotaxi development with very little to show for its investment.” Things change, such as who controls the U.S. regulatory regime. Expect presidential policy-making to soon favor an EV skeptic like President-elect Donald Trump, enamored as he is with a last-century manufacturing caricature powered by gasoline. Say goodbye to $7,500 tax subsidies on qualifying EVs and hello to tariffs on, say, Mexican-built Ford Mustang Mach-Es — Trump-driven moves that threaten to sap the profitability Detroit needs to fund its EV programs. Add persistent consumer skepticism fueled by still-spotty charging infrastructure and steep EV prices crashing headlong into the technological promise touted by Silicon Valley, Detroit and their legacy rivals. Worse, the capital demands for developing technology outside the wheelhouse of more traditional automakers like GM are totaling too much, especially when there's real money to be made on ICE vehicles in Trump World. And the fact that Detroit is trying to compete with the most technologically adept, most well-capitalized (read "richest") companies on the planet — for whose market cap $10 billion in sunk capital is almost pocket change — should crystalize the scope of the challenge GM and its legacy rivals face now and into the future. The simple fact is this: the business ecosystems colliding in the electrified AV space, where each regards the other with derision and misunderstanding, misread the complexity of their undertaking. Tech sharpies figured building vehicles to comport with safety regs and enabling them to drive themselves would be comparatively easy, and industry motorheads bet they could fund their technological odyssey into a brave new (and unfamiliar) world with profits earned on full-sized pickups and SUVs. Both sides miscalculated, misguided in part by fervor from Wall Street, the environmental lobby and a post-pandemic Biden administration. The president and his people believed a green automotive future would be nigh if only the government could offer enough tax subsidies and manufacturing grants to a) realize the vision and b) stymie China's government-backed EV behemoth. Consumer demand? Meh, they'll come around. Not enough of them have, yet, unsurprisingly preferring what they know. As much as Detroit's automakers want to divorce themselves from their "legacy" past they can't persuasively deny their history, geographic footprint and automotive heritage. And distancing themselves from their core competency in a bid to change the narrative about what they are is not without peril. GM's not alone in its conundrum. Ford Motor Co. and Volkswagen AG bolted their autonomous vehicle gigs a few years back now. Apple Inc., the do-no-wrong heaviest of tech heavyweights, bagged its autonomous car that terrified legacy auto executives simply because it would be an Apple product. Musk endured production “hell” with the launch of his Tesla 3, demonstrating that building a car the right way is harder and less profitable than it looks. The shift to electrification and self-driving vehicles is not a destination whose arrival can be guaranteed — as GM, its industry rivals and Silicon Valley players are learning, sometimes in expensive and humbling ways. It's a journey, and it's just beginning. ©
Gus Malzahn is leaving his post as UCF's head coach to reunite with Florida State coach Mike Norvell as the Seminoles' offensive coordinator, ESPN reported on Saturday. Norvell, who served as a graduate assistant under Malzahn at Tulsa in 2007-08, relinquished his role as FSU's primary playcaller amid a staff shakeup this season. Florida State, 1-7 in the Athletic Coast Conference this season, entered Saturday's season finale against Florida at 2-9 and ranked No. 131 in the nation in total offense. UCF also endured a tough 2024 season, going 4-8 after losing eight of its last nine games. During Malzahn's four-year tenure, the Knights went 28-24, including 5-13 in the Big 12 Conference the last two seasons. Malzahn, 59, is 105-62 in 13 seasons as a college head coach, highlighted by a 68-35 mark in eight seasons at Auburn -- which included a BCS title game appearance in 2013. He served as offensive coordinator and playcaller when the Tigers won the national title in 2010. Malzahn will be tasked with revitalizing a Florida State offense that helped produce a 13-1 campaign in 2023, when the Seminoles were denied a spot in the College Football Playoff. Over the last three seasons at UCF, his rushing attack has been in the Top 10 in the nation. In his 19 seasons as a college head coach or offensive coordinator, Malzahn's teams have averaged 447.7 yards per game, and three of his teams eclipsed 7,000 yards in a season. --Field Level MediaThe demands of achieving both one-day shipping and a satisfying orgasm collide in Halina Reijn’s “Babygirl,” a kinky and darkly comic erotic thriller about sex in the Amazon era. Nicole Kidman stars as Romy Mathis, the chief executive of Tensile, a robotics business that pioneered automotive warehouses. In the movie’s opening credits, a maze of conveyor belts and bots shuttle boxes this way and that without a human in sight. Romy, too, is a little robotic. She intensely presides over the company. Her eyes are glued to her phone. She gets Botox injections, practices corporate-speak presentations (“Look up, smile and never show your weakness”) and maintains a floor-through New York apartment, along with a mansion in the suburbs that she shares with her theater-director husband ( Antonio Banderas ) and two teenage daughters (Esther McGregor and Vaughan Reilly). But the veneer of control is only that in “Babygirl,” a sometimes campy, frequently entertaining modern update to the erotically charged movies of the 1990s, like “Basic Instinct” and “9 1/2 Weeks.” Reijn, the Dutch director of “Bodies Bodies Bodies” has critically made her film from a more female point of view, resulting in ever-shifting gender and power dynamics that make “Babygirl” seldom predictable — even if the film is never quite as daring as it seems to thinks it is. The opening moments of “Babygirl,” which A24 releases Wednesday, are of Kidman in close-up and apparent climax. But moments after she and her husband finish and say “I love you,” she retreats down the hall to writhe on the floor while watching cheap, transgressive internet pornography. The breathy soundtrack, by the composer Cristobal Tapia de Veer, heaves and puffs along with the film’s main character. One day while walking into the office, Romy is taken by a scene on the street. A violent dog gets loose but a young man, with remarkable calmness, calls to the dog and settles it. She seems infatuated. The man turns out to be Samuel (Harris Dickinson), one of the interns just starting at Tensile. When they meet inside the building, his manner with her is disarmingly frank. Samuel arranges for a brief meeting with Romy, during which he tells her, point blank, “I think you like to be told what to do.” She doesn’t disagree. Some of the same dynamic seen on the sidewalk, of animalistic urges and submission to them, ensues between Samuel and Romy. A great deal of the pleasure in “Babygirl” comes in watching Kidman, who so indelibly depicted uncompromised female desire in Stanley Kubrick’s “Eyes Wide Shut,” again wade into the mysteries of sexual hunger. “Babygirl,” which Reijn also wrote, is sometimes a bit much. (In one scene, Samuel feeds Romy saucers of milk while George Michael’s “Father Figure” blares.) But its two lead actors are never anything but completely magnetic. Kidman deftly portrays Romy as a woman falling helplessly into an affair; she both knows what she’s doing and doesn’t. Dickinson exudes a disarming intensity; his chemistry with Kidman, despite their quickly forgotten age gap, is visceral. As their affair evolves, Samuel’s sense of control expands and he begins to threaten a call to HR. That he could destroy her doesn’t necessarily make Romy any less interested in seeing him, though there are some delicious post-#MeToo ironies in their clandestine CEO-intern relationship. Also in the mix is Romy’s executive assistant, Esme (Sophie Wilde, also very good), who’s eager for her own promotion. Where “Babygirl” heads from here, I won’t say. But the movie is less interested in workplace politics than it is in acknowledging authentic desires, even if they’re a little ludicrous. There’s genuine tenderness in their meetings, no matter the games that are played. Late in the film, Samuel describes it as “two children playing.” As a kind of erotic parable of control, “Babygirl” is also, either fittingly or ironically, shot in the very New York headquarters of its distributor, A24. For a studio that’s sometimes been accused of having a “house style,” here’s a movie that goes one step further by literally moving in. What about that automation stuff earlier? Well, our collective submission to digital overloads might have been a compelling jumping-off point for the film, but along the way, not every thread gets unraveled in the easily distracted “Babygirl.” Saucers of milk will do that. “Babygirl,” an A24 release, is rated R by the Motion Picture Association for “strong sexual content, nudity and language.” Running time: 114 minutes. Three stars out of four.
Forest Officers Of Three Tiger Reserves To Plan Elephant Control Strategy In Madhya PradeshHe did enough in Friday's 19-17 loss at Kansas City to show that Las Vegas' quarterback job will be his for the rest of the season — barring, that is, another injury. O'Connell didn't look like a quarterback who hadn't played in nearly six weeks because of a broken thumb . Plus, the Raiders had a short week to prepare for the Chiefs, meaning O'Connell only went through a series of walk-through practices. Even so, he completed 23 of 35 passes for 340 yards, including touchdown passes of 33 yards to tight end Brock Bowers and 58 yards to wide receiver Tre Tucker. He didn't throw any interceptions. “Thought he competed,” coach Antonio Pierce said Saturday morning. “I thought for what we knew we were getting with Spags (Kansas City defensive coordinator Steve Spagnuolo) and that defense, that he stood in the pocket, made some tough throws, took some hits, took the shots down the field like we wanted. We had some opportunities to take shots down the field, he threw them. And I thought our skill guys did a hell of a job competing and making some really good plays for us.” O'Connell's performance would've shined even more if not for the Raiders' final offensive play. He led the Raiders from their 8-yard line to the Chiefs 32 with 15 seconds left. The plan was for O'Connell to take the snap and throw the ball away to run off a few more seconds, then send Daniel Carlson out for the potential winning field goal without giving Patrick Mahomes enough time to mount one of his signature comebacks. But rookie center Jackson Powers-Johnson snapped the ball before O'Connell was expecting it, and the Chiefs recovered to secure another close, last-minute victory. The Raiders were called for illegal shift, which Kansas City declined. But there was some question about whether officials intended to call a false start instead. Though that infraction would have cost Las Vegas 5 yards, the pre-snap penalty still would've given Carlson a shot at the field goal. Pierce said his team heard an official's whistle before the snap, and that will be included in the Raiders' report to the NFL. “We do that every game,” Pierce said. “Typically, anywhere from three to five questions, and then we’ll get a letter within 24 to 36 hours, and we’ll read it and learn from it.” Bowers had another sensational game. He was targeted 14 times, catching 10 passes for 140 yards. For the season, he has 84 receptions for 884 yards and four TDs, making him a strong contender for Offensive Rookie of the Year. “We’re seeing double-teams and them really shifting their zone to him, and I don’t really think it matters,” Pierce said. “I think we've got a really special player on our hand.” The Raiders need to do better on first and second downs to set up more favorable third-down conversions. They have faced 47 third downs from 7 to 10 yards, tied with the Dallas Cowboys for fifth most. Las Vegas' conversion rate on those plays is 36.2%, which actually is favorable compared to the rest of the league, but the Raiders are still creating too many of those situations. Las Vegas made life difficult for Mahomes, sacking him five times. And it wasn't just Maxx Crosby bringing the heat. Four players had at least one-half sack, including K’Lavon Chaisson, who had 1 1/2. It was a season-high total for the Raiders, and they have taken down the opposing quarterback in 30 consecutive games, the third-longest active streak. Carlson is usually money, but he missed field goals from 56, 55 and 58 yards. Hardly chip shots, but he is capable of converting from those distances. He had made 30 of 38 field goals from 50-plus yards entering the game, with a career long of 57 yards. WR DJ Turner injured his knee in the second half. 12 — The Raiders are one of three teams to fall behind double digits in each of their first 12 games of a season. The others were the 1986 Indianapolis Colts and 1972 New England Patriots. The Raiders visit Tampa Bay on Dec. 8. AP NFL: https://apnews.com/hub/nfl
Citing Hunter Biden pardon, Trump asks judge to dismiss his criminal hush money case
By KATE BRUMBACK ATLANTA (AP) — A judge is weighing whether a Georgia state Senate committee has the right to subpoena testimony and documents from Fulton County District Attorney Fani Willis as it looks into whether she has engaged in misconduct during her prosecution of President-elect Donald Trump. The Republican-led committee sent subpoenas to Willis in August seeking to compel her to testify at its September meeting and to produce scores of documents. The committee was formed earlier this year to examine allegations of “various forms of misconduct” by Willis, an elected Democrat, during her prosecution of Trump and others over their efforts to overturn the former president’s 2020 election loss in Georgia. Willis’ attorney, former Democratic Gov. Roy Barnes, told Fulton County Superior Court Judge Shukura Ingram during a hearing Tuesday that although the Georgia General Assembly has subpoena power, that power is not automatically conferred on a single legislative chamber or its committees. Even if the committee did have such power, he argued, the subpoenas in question are overly broad and not related to a legitimate legislative need. Barnes said the focus on Willis and her investigation into Trump shows that the committee was politically motivated and not a legitimate inquiry into the practices of district attorneys’ offices: “What they were trying to do is chill the prosecution of Donald Trump and find out what they had.” Josh Belinfante, a lawyer representing the lawmakers, said there is nothing in the Georgia Constitution that prohibits the Senate from issuing a subpoena. The duly formed interim committee is looking into whether new legislation is needed to regulate the practices of district attorneys’ offices in the state, he argued. “They are investigating and making an inquiry into these allegations that may show that existing state laws, including those establishing the processes for selecting, hiring and compensating special assistant district attorneys, are inadequate,” Belinfante said. The resolution creating the committee focused in particular on Willis’ hiring of special prosecutor Nathan Wade , with whom she had a romantic relationship , to lead the prosecution against Trump and others. It says the relationship amounted to a “clear conflict of interest and a fraud upon the taxpayers” of the county and state. One of the committee’s subpoenas orders Wills to produce documents related to Wade, including documents related to his hiring and payment, documents related to money or items of value that Wade and Willis may have exchanged, text messages and emails between the two, and their phone records. The committee also requested any documents her office sent in response to requests from the U.S. House, as well as communications Willis and her office had with the White House, the U.S. Justice Department and the House relating to the 2020 presidential election. And they asked for documents related to federal grant money Willis’ office has received. Before the deadlines in the subpoenas, Willis challenged them in court. Willis’ challenge was pending in mid-September when she skipped a hearing during which the committee members had hoped to question her. In October, the committee asked Ingram to require Willis to comply with the subpoenas. The committee’s lawyers wrote in a court filing that Willis’ failure to do so had delayed its ability to finish its inquiry and to provide recommendations for any legislation or changes in appropriations that might result. Barnes also argued that once the regular legislative session has adjourned, which happened in March this year, legislative committees can meet to study issues and come up with recommendations but do not have the power to compel someone to appear or produce documents. Belinfante rejected that, saying the state Constitution expressly permits the creation of interim committees and allows them to make their rules. Even if these subpoenas were validly issued, Barnes argued, they ask for too much, including private and personal information that is not a legitimate target of a legislative subpoena. Belinfante said the lawmakers are simply trying to do their jobs. He asked that Willis be ordered to appear before the committee in early January. He also asked that she be ordered to provide the requested documents and explain what privilege justifies any that are excluded. With a glaring lack of state case law on the issue of the General Assembly’s subpoena power, that’s one issue Ingram will have to address. She said she will consider the arguments and release her order as soon as she can. Willis and Wade have acknowledged that they had a relationship but have said it began after he was hired and ended before the indictment against Trump was filed. Trump and other defendants argued that the relationship created a conflict of interest that should disqualify Willis and her office from continuing with her prosecution of the case. Fulton County Superior Court Judge Scott McAfee ruled in March that Willis’ actions showed a “tremendous lapse in judgment,” but he did not find a conflict of interest that would disqualify Willis. He said she could continue her prosecution as long as Wade stepped aside, which he did. Trump and others have appealed that ruling to the Georgia Court of Appeals, and that appeal remains pending.
Trump backs dockworkers' fight against automation. He risks price hikes, experts say
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenCaught in the debate
Betts voted postseason MVP by New York baseball writers, Judge wins fourth NY player of the yearVice President Kashim Shettima has restated the Government of the Federal commitment to improving healthcare delivery in Nigeria, especially in rural areas. VP Shettima specifically recognised the critical role of medical professionals in Nigeria’s healthcare ecosystem, assuring of the government’s commitment to supporting and retaining healthcare talent in the country. Speaking during a visit by a delegation from the West African College of Physicians (WACP), Shettima in a statement by his spokesman, Stanley Nkwocha commended healthcare professionals for their dedication to serving the nation, despite challenges. “Yours is a very noble profession and many of the young ones are opting to leave the country but you did not. It’s not because you have not had options, but you felt a moral obligation to stay at home and serve,” he said. The Vice President assured the delegation that the President Bola Tinubu-led government is committed to addressing healthcare challenges. He highlighted the appointment of Professor Ali Pate as the Coordinating Minister for Health and Social Welfare, noting the Minister’s deep understanding of the health sector. “We will treat members of our professional bodies with dignity and respect. We will provide the enabling ground for you to work in Nigeria,” Shettima promised. Recalling his efforts to support healthcare education in Borno State, the Vice President said, “In 2014, as governor of Borno State, I took it upon myself to sponsor female citizens of the state to study Medicine and Surgery in Sudan. “The students have all graduated and licensed by the Medical and Dental Council of Nigeria (MDCN) to practice medicine in Nigeria and are under the employment of the state government,” he stated. He emphasised the government’s moral obligation to assist the people, saying, “We have a moral obligation to assist our people. In the fullness of time, we will have a course to rejoice. We will support you.” Earlier, the leader of the delegation, Dr. Jeremiah Madaki, thanked the Vice President for his support for the 48th Annual General and Scientific Conference of the West African College of Physicians. Madaki expressed optimism about the government’s commitment to improving healthcare systems, even as he shared the communique of the conference with the Vice President. “We are here to thank you for your encouragement and for advancing discussions on health system revitalisation under the President Bola Ahmed Tinubu’s Renewed Hope Agenda,” he said. Dr. Madaki also assured of the College’s commitment to policy advocacy and its plans to work closely with the government to implement evidence-based policies that improve healthcare outcomes in Nigeria. Other members of the delegation included Dr. Habibu Galadanci, Dr. Ogugua Osi-Ogbu and Dr. Tahir Umar.Bank of America signs again with FIFA for US-hosted Club World Cup that still has no TV deals
Judge weighs whether to order Fani Willis to comply with lawmakers’ subpoenas over Trump caseBrian Arteaga Launches Legal Match Experts to Transform Access to Legal Representation
QINGDAO, China, Dec. 24, 2024 (GLOBE NEWSWIRE) -- SOS Limited ("SOS" or the "Company") (NYSE: SOS ) today announced that on May 15, 2024, the Company filed its annual report on Form 20-F for the year ended December 31, 2023 (the "Form 20-F”) with the U.S. Securities and Exchange Commission (the "SEC"). In compliance with the New York Stock Exchange rules, the Form 20-F is available on the Company's website at http://www.sosyun.com/ . In addition, all shareholders of the Company may request, free of charge, a hard copy of the Company's complete audited financial statements filed with the SEC. To request a hard copy of the Company's audited financial statements, or for any other inquiry in respect of this press release, please contact the Investor Relations Department of the Company, whose contact information is as follows: [email protected] Safe Harbor Statement This press release contains forward-looking statements made under the "safe harbor" provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. SOS may also make written or oral forward-looking statements in its reports filed with or furnished to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about SOS' beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is current as of the date of the press release, and SOS does not undertake any obligation to update such information, except as required under applicable law. About SOS Limited SOS is an emerging blockchain-based and big data-driven marketing solution provider. SOS is also engaged in blockchain and cryptocurrency operations, which currently include cryptocurrency mining and may expand into cryptocurrency security and insurance in the future. Since April 2021, we launched commodity trading via our subsidiary SOS International Trading Co. Ltd and Weigou International Trading Co Ltd. Major trading commodity includes mineral resin, soybean, wheat, sesame, liquid sulfur, petrol coke and latex etc. For more information, please visit: http://www.sosyun.com/ . Contact: Investor Relations [email protected] SOURCE - SOS Limited
Is Enron back? If it’s a joke, some former employees aren’t laughing
Trump wants to end daylight saving time. What it could mean for Oregon